Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.

Breast (Edinburgh, Scotland) - 1 Oct 2026

Liu Shixian, Wang Kaixuan, Chen Hao, Wan Ziming, Dou Lei, Li Shunping

Abstract excerpt

PURPOSE: Inavolisib plus palbociclib and fulvestrant has been approved for treating PIK3CA-mutated, hormone receptor-positive human epidermal growth factor receptor 2-negative (HR + HER2-), advanced breast cancer in the USA. This study evaluated the cost-effectiveness of inavolisib plus palbociclib and fulvestrant compared with palbociclib plus fulvestrant from the US payer perspective. METHODS: We developed a...

Read the complete abstract on PubMed

Topics

Humans
Breast Neoplasms
Female
Pyridines
Cost-Benefit Analysis
Cost-Effectiveness Analysis
Piperazines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Fulvestrant

United States

Quality-Adjusted Life Years

Antineoplastic Combined Chemotherapy Protocols

Class I Phosphatidylinositol 3-Kinases

Mutation

Middle Aged

Imidazoles

Oxazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 42543051
DOI: 10.1016/j.breast.2026.104889
PMCID: PMC13453036

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.PMID 42543051Read ↗

Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.Semantic proximity Read ↗

Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer.Semantic proximity Read ↗

Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?Semantic proximity Read ↗

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.Semantic proximity Read ↗

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.Semantic proximity Read ↗

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read ↗

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Semantic proximity Read ↗

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.